Evidence map›Paper›PMID 31654770›Full record

ArticleCellular and molecular gastroenterology and hepatology2020

Tributyrin Inhibits Ethanol-Induced Epigenetic Repression of CPT-1A and Attenuates Hepatic Steatosis and Injury.

Hridgandh Donde, Smita Ghare, Swati Joshi-Barve, JingWen Zhang, Manicka V Vadhanam, Leila Gobejishvili, Pawel Lorkiewicz, Sanjay Srivastava, Craig J McClain, Shirish Barve

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 51 citations in OpenAlex.

  1. The histone deacetylase family in health and disease.Signal transduction and targeted therapy · 2026
    Review
  2. [Histone deacetylases and alcohol-related liver disease].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Frontiers in pharmacology · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hridgandh DondeDepartment of Medicine, University of Louisville, Louisville, Kentucky; University of Louisville Alcohol Research Center, University of Louisville, Louisville, Kentucky.
Smita GhareDepartment of Medicine, University of Louisville, Louisville, Kentucky; University of Louisville Alcohol Research Center, University of Louisville, Louisville, Kentucky; Hepatobiology and Toxicology Center, University of Louisville, Louisville, Kentucky.
Swati Joshi-BarveDepartment of Medicine, University of Louisville, Louisville, Kentucky; University of Louisville Alcohol Research Center, University of Louisville, Louisville, Kentucky; Hepatobiology and Toxicology Center, University of Louisville, Louisville, Kentucky; Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky.
JingWen ZhangDepartment of Medicine, University of Louisville, Louisville, Kentucky; University of Louisville Alcohol Research Center, University of Louisville, Louisville, Kentucky.
Manicka V VadhanamDepartment of Medicine, University of Louisville, Louisville, Kentucky; University of Louisville Alcohol Research Center, University of Louisville, Louisville, Kentucky.
Leila GobejishviliDepartment of Medicine, University of Louisville, Louisville, Kentucky; University of Louisville Alcohol Research Center, University of Louisville, Louisville, Kentucky; Hepatobiology and Toxicology Center, University of Louisville, Louisville, Kentucky.
Pawel LorkiewiczDepartment of Medicine, University of Louisville, Louisville, Kentucky; University of Louisville Superfund Research Center, University of Louisville, Louisville, Kentucky.
Sanjay SrivastavaDepartment of Medicine, University of Louisville, Louisville, Kentucky; University of Louisville Superfund Research Center, University of Louisville, Louisville, Kentucky.
Craig J McClainDepartment of Medicine, University of Louisville, Louisville, Kentucky; University of Louisville Alcohol Research Center, University of Louisville, Louisville, Kentucky; Hepatobiology and Toxicology Center, University of Louisville, Louisville, Kentucky; Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky; Robley Rex Veterans Affairs Medical Center, Louisville, Kentucky.
Shirish BarveDepartment of Medicine, University of Louisville, Louisville, Kentucky; University of Louisville Alcohol Research Center, University of Louisville, Louisville, Kentucky; Hepatobiology and Toxicology Center, University of Louisville, Louisville, Kentucky; Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky. Electronic address: shirish.barve@louisville.edu.
University of Louisville · US

Funding

Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2016 to 2025
$24.1M
Superfund Training CoreP42ES023716 · NIEHS · UNIVERSITY OF LOUISVILLE · PI SRIVASTAVA, SANJAY · 2017 to 2025
$18.1M
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN · 2016 to 2026
$17.9M
Project 5 - Metabolomic Analysis of AtherothrombosisP20GM103492 · NIGMS · UNIVERSITY OF LOUISVILLE · PI HONG, KYUNG UK · 2012 to 2017
$13.8M
TBDP30GM127607 · NIGMS · UNIVERSITY OF LOUISVILLE · PI BHATNAGAR, ARUNI · 2018 to 2022
$6.3M
Role of Gut Microbiome and DHA Deficiency in Alcohol Induced NeuroinflammationU01AA022618 · NIAAA · UNIVERSITY OF LOUISVILLE · PI BARVE, SHIRISH S · 2016 to 2020
$1.7M
SAM Deficiency Mediated Epigenetic Mechanisms in Alcohol induced ImmunosuppressionR01AA024405 · NIAAA · UNIVERSITY OF LOUISVILLE · PI BARVE, SHIRISH S · 2015 to 2019
$1.6M
NIAAA NIH HHS P50 AA024337NIAAA NIH HHS R01 AA024405NIAAA NIH HHS U01 AA022618NIEHS NIH HHS P42 ES023716NIGMS NIH HHS P20 GM103492NIGMS NIH HHS P20 GM113226NIGMS NIH HHS P30 GM127607
6 · The paper itself

Abstract

Ethanol-mediated down-regulation of carnitine palmitoyltransferase-1 (CPT-1A) gene expression plays a major role in the development of hepatic steatosis; however, the underlying mechanisms are not completely elucidated. Tributyrin, a butyrate prodrug that can inhibit histone deacetylase (HDAC) activity, attenuates hepatic steatosis and injury. The present study examined the beneficial effect of tributyrin/butyrate in attenuating ethanol-induced pathogenic epigenetic mechanisms affecting CPT-1A promoter-histone modifications and gene expression and hepatic steatosis/injury.

methodsMice were fed a liquid Lieber-DeCarli diet (Research Diet Inc, New Brunswick, NJ) with or without ethanol for 4 weeks. In a subset of mice, tributyrin (2 g/kg) was administered orally by gavage. Primary rat hepatocytes were treated with 50 mmol/L ethanol and/or 2 mmol/L butyrate. Gene expression and epigenetic modifications at the CPT-1A promoter were analyzed by chromatin immunoprecipitation analysis.

resultsIn vivo, ethanol induced hepatic CPT-1A promoter histone H3K9 deacetylation, which is indicative of a repressive chromatin state, and decreased CPT-1A gene expression. Our data identified HDAC1 as the predominant HDAC causing CPT-1A promoter histone H3K9 deacetylation and epigenetic down-regulation of gene expression. Significantly, Specificity Protein 1 (SP1) and Hepatocyte Nuclear Factor 4 Alpha (HNF4α) participated in the recruitment of HDAC1 to the proximal and distal regions of CPT-1A promoter, respectively, and mediated transcriptional repression. Importantly, butyrate, a dietary HDAC inhibitor, attenuated ethanol-induced recruitment of HDAC1 and facilitated p300-HAT binding by enabling SP1/p300 interaction at the proximal region and HNF4α/peroxisomal proliferator-activated receptor-γ coactivator-1α/p300 interactions at the distal region, leading to promoter histone acetylation and enhanced CPT-1A transcription.

conclusionsThis study identifies HDAC1-mediated repressive epigenetic mechanisms that underlie an ethanol-mediated decrease in CPT-1A expression. Importantly, tributyrin/butyrate inhibits HDAC1, rescues CPT-1A expression, and attenuates ethanol-mediated hepatic steatosis and injury, suggesting its potential use in therapeutic strategies for alcoholic liver disease.

Indexed as

AcetylationAdministration, OralAnimalsCarnitine O-PalmitoyltransferaseCells, CulturedChemical and Drug Induced Liver InjuryDisease Models, AnimalDown-RegulationDrug Evaluation, PreclinicalEpigenetic RepressionEthanolFatty Liver, AlcoholicHepatocytesHistone Deacetylase InhibitorsHistonesHumansCarnitine O-PalmitoyltransferaseCPT1B protein, mouseEthanolHistone Deacetylase InhibitorsHistonestributyrinTriglyceridesAlcoholic Liver DiseaseEpigenetic Promoter ModificationGene RegulationHepatocytes

Identifiers

PMID31654770
PMCPMC7078548
OpenAlexW2981385529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.